Boston, MA -- (SBWIRE) -- 11/18/2014 -- ADHD is a psychiatric disorder, which is mostly found in children. However, adults have also been reported to be diagnosed with ADHD. The patients with ADHD suffer from several problems including hyperactivity, impulsiveness, and lack of focus and concentration. The causes of ADHD are not known. It is believed to be linked with genetic and environmental causes. However, it has been reported to be related with the decrease in the extraneuronal levels of norepinephrine and dopamine. In addition, the patients have an abnormality in the brain structure. It is more prevalent in boys than girls. The management of ADHD is done by counseling, medications, and lifestyle changes.

TechNavio's analysts forecast the Global ADHD Drugs market to grow at a CAGR of 5.33 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global ADHD Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various therapies used in the treatment of ADHD, which include:

View Full Report Details and Table of Contents

- Stimulants
- Non-stimulants

TechNavio's report, the Global ADHD Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global ADHD Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions:

- Americas
- APAC
- EMEA

Key Vendors:

- Eli Lilly and
- Janssen
- Novartis
- Shire

Other Prominent Vendors:

- Actavis
- Alcobra
- Amarantus
- Boehringer Ingelheim
- Concordia
- Curemark
- GlaxoSmithKline
- Hisamitsu
- Impax
- Intellipharmaceutics
- Mylan
- Neurovance
- Noven
- Par Pharmaceuticals
- Sanofi
- Shionogi
- Sunovion
- Teva
- Tris Pharma

Market Driver:

- Presence of Unmet Need
- For a full, detailed list, view our report

Market Challenge:

- Unknown Etiology
- For a full, detailed list, view our report

Market Trend:

- Increase in Awareness
- For a full, detailed list, view our report

Key Questions Answered in this Report:

- What will the market size be in 2018 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

Companies Mentioned in this Report: Eli Lilly and, Janssen, Novartis, Shire, Actavis, Alcobra, Amarantus, Boehringer Ingelheim, Concordia, Curemark, GlaxoSmithKline, Hisamitsu, Impax, Intellipharmaceutics, Mylan, Neurovance, Noven, Par Pharmaceuticals, Sanofi, Shionogi, Sunovion, Teva, Tris Pharma

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 800-844-8156

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations
- Global Infectious Disease Treatment Market 2014-2018
- Global Generic Drugs Market 2014-2018
- Global Pain Management Drugs Market 2014-2018
- Global CRAMS Market Outlook to 2018 - India and China Present Bright Prospects
- Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2014
- Global Multiple Sclerosis Drugs Market 2014-2018
- Global Dermatological Drugs Market 2014-2018
- Biosimilars Market - Global Forecast to 2018
- Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2014